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Summary
Introduction: The treatment of postoperative mediastinitis is very important because of its high
morbidity, mortality, and increased hospital stay and hospital costs. The aims of our research
were to investigate whether linezolid alone can be an effective treatment agent for methicillin-
resistant Staphylococcus aureus (MRSA) mediastinitis, and to determine whether linezolid can
provide synergistic activity when given in combination with rifampin.
Methods: A partial upper median sternotomy was performed on 70 rats. The animals were
divided into seven groups: an uncontaminated control group; an untreated contaminated group;
three contaminated groups that received antibiotic therapy with either 25 or 50 mg/kg linezolid
twice a day, or rifampin 5 mg/kg twice a day; and two contaminated groups that received a
combination therapy consisting of 25 or 50 mg/kg linezolid and rifampin 5 mg/kg twice a day. The
antibiotic treatment lasted 7 days. Tissue samples from the upper ends of the sternum and swab
specimens of the upper mediastinum were obtained and evaluated microbiologically.
Results: The 25-mg/kg dose of linezolid, either alone or combined with rifampin, was not
effective in reducing the bacterial counts in mediastinum and sternum. Quantitative bacterial
cultures of mediastinum and sternum were significantly lower in the groups receiving 50 mg/kg
linezolid alone or in combination with rifampin compared with the control. Adding of rifampin to
linezolid therapy did not result in a significant change in bacterial counts versus linezolid alone.
Conclusion: A high dose of linezolid should be considered as a possible therapeutic agent for the
treatment of post-sternotomy infection caused by MRSA.
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Although postoperative mediastinitis after open heart sur-
gery is a rare complication, it is associated with amortality of
up to 47% and increased hospital stay and hospital costs.1—3
Staphylococci are the main causative organisms, accounting
for 54—79% of cases.1,4 Staphylococcus aureus mediastinitis
often occurs due to perioperative contamination of the
mediastinal space.2 Methicillin-resistant Staphylococcus aur-
eus (MRSA)mediastinitis has been found to be associated with
higher rates of overall mortality, mediastinitis-related death,
and treatment failure.5
Optimal outcomes in post-surgical mediastinitis require
surgical management in addition to systemic antibiotic ther-
apy.6—8 MRSA is showing an increasing prevalence worldwide
and most strains are now also resistant to fluoroquinolones,
macrolides, tetracyclines, and aminoglycosides.9,10 Since the
antibiotics used traditionally for the treatment of serious
infections caused by these resistant staphylococci are lim-
ited, there is a requirement for new therapeutic approaches.
Linezolid is a synthetic oxazolidinone antimicrobial agent
that has a good activity against most medically important
Gram-positive microorganisms resistant to methicillin and
vancomycin.11,12 Recently dual or multi-drug combinations
have been encouraged in the hope of preventing antibiotic
resistance.13,14 Rifampin is highly bactericidal towards Sta-
phylococcus species.15 Several trials of linezolid, alone or in
combination with rifampin, have been published;16—19 how-
ever, its efficacy and safety in mediastinitis are less well
reported.
The aims of our research were to investigate whether
linezolid alone can be an effective treatment agent for MRSA
mediastinitis, and to determine whether linezolid can pro-
vide synergistic activity when given in combination with
rifampin.
Methods
This study was approved by the local animal research ethics
committee. During the entire study the animals were kept at
our institution’s animal research laboratory under veterinary
supervision. All animals received human care in compliance
with Principles of laboratory animal care, formulated by the
Guide for the care and use of laboratory animals, prepared
by the National Academy of Sciences.20
Organisms and susceptibility testing
The strain of MRSA used in this study was isolated from blood
culture and a surgical site infection specimen from a patient
with post-sternotomy mediastinitis following open heart sur-
gery. Identification of the clinical isolates was determined by
Gram staining, catalase reaction, tube coagulation test, and
Api-Staph test (bioMe´rieux, Lyon, France). Methicillin sensi-
tivity was investigated by oxacillin disk diffusion test.21
The antimicrobial susceptibility of the strain was deter-
mined by using the broth microdilution method, according to
the procedures outlined by the Clinical and Laboratory Stan-
dards Institute specifications.22,23 The minimum inhibitory
concentration was taken to be the lowest antibiotic concen-
tration at which observable growth was inhibited.Drugs
Linezolid (Pfizer, Halden, Norway) and rifampin (Kocak
Farma, Istanbul, Turkey) were diluted in accordance with
the manufacturers’ recommendations. Solutions of drugs
were made fresh on the day of assay.
In vivo rat model
Seventy adult male Wistar rats weighing between 300 and
350 g were randomly divided into seven groups. There were
10 rats in each group. Group 1was an uncontaminated control
group with no contamination and no antibiotic therapy given;
group 2 was an untreated contaminated control group with
local MRSA contamination and no antibiotic therapy given;
group 3 consisted of those with local MRSA contamination
given intraperitoneal linezolid (25 mg/kg of body weight)
twice a day; group 4 consisted of those with local MRSA
contamination given intraperitoneal linezolid (50 mg/kg of
body weight) twice a day; group 5 consisted of those with
local MRSA contamination given intramuscular rifampin
(5 mg/kg of body weight) twice a day; group 6 consisted of
those with local MRSA contamination given intraperitoneal
linezolid (25 mg/kg of body weight) and intramuscular rifam-
pin (5 mg/kg of body weight) twice a day; group 7 consisted
of those with local MRSA contamination given intraperitoneal
linezolid (50 mg/kg of body weight) and intramuscular rifam-
pin (5 mg/kg of body weight) twice a day.
Each rat was anesthetized intramuscularly with a 2:1
mixture of ketamine hydrochloride (100 mg/ml; Pfizer) and
xylazine hydrochloride (20 mg/ml; Bayer) at a dose of
0.75 ml/kg. The hair on the rats’ chests was shaved, the skin
cleaned with 10% povidone-iodine solution, and a sterile
towel was used to cover the sternum. The skin and presternal
layers were incised. A partial upper median sternotomy
without access to pleural spaces was performed on all rats.
Groups 2—7 were inoculated with 0.5 ml 108 colony-forming
units (CFU)/ml MRSA in the mediastinal and in the sternal
layers. The sternum and the presternal layers were closed
with a single 3-0 Prolene suture. Animals were returned to
individual cages and examined thoroughly daily. During the
treatment period no medication was given to the rats in
groups 1 and 2. Postoperatively, groups 3—7 were given
antibiotic treatment for seven days, twice daily, starting
24 hours after the end of the procedure. After 12 hours
following the end of treatment, the rats were sacrificed, a
sternotomy was performed for each rat, and tissue samples
from the upper ends of the sternum and swab specimens of
the upper mediastinum were aseptically obtained.
Assessment of the infection
Mediastinal swab specimens were placed in tubes containing
1 ml of phosphate-buffered saline solution and sonicated for
5 minutes. Quantitation of viable bacteria was performed by
culturing serial 10-fold dilutions (0.1 ml) of the bacterial
suspension on blood agar plates. All plates were incubated
at 37 8C for 48 hours and evaluated for the presence of the
staphylococcal strains. The organisms were quantitated by
counting the number of CFU per plate. Tissue samples were
weighed and homogenized under sterile conditions in 1 ml of
sterile phosphate-buffered saline. The serial diluted homo-
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bated at 37 8C. After 48 hours, the amount of growing bac-
teria was determined as CFU/g tissue.
Statistical analysis
Quantitative culture results were presented as arithmetic
mean  standard deviation (SD) of CFU. Differences among
the groups were evaluated using one-way analysis of variance
(ANOVA), andmultiple comparisons between the groups were
performedwith a posthoc test (Tukey’s HSD test). Differences
were considered statistically significant when p < 0.05. Data
were analyzed using statistical software SPSS for Windows
11.0 (SPSS, Chicago, IL, USA).
Results
According to the broth microdilution method, the clinical
isolate was susceptible to linezolid and rifampin. The mini-
mal inhibitory concentrations (MICs) for linezolid and rifam-
pin in the strain of S. aureus used in this study were found to
be 2 mg/ml and 0.5 mg/ml, respectively.
Evidence of mediastinitis was present in all rats of the
untreated contaminated group. In contrast, none of the
animals included in the uncontaminated control group had
anatomic ormicrobiological evidence ofmediastinitis. All the
rats in the groups that received antibiotic treatment, except
two rats in group 4 and a rat in group 7, showed evidence of
infection. Culture negative rates and bacterial counts for
each group are shown in Table 1.
The average growth of the microorganisms in the med-
iastinum and sternum were compared. The 25-mg/kg dose of
linezolid, either alone or combined with rifampin, was not
effective in reducing the bacterial counts inmediastinum and
sternum in comparison with the contaminated untreated
group ( p > 0.05). Quantitative bacterial cultures of medias-
tinum and sternum were significantly lower in the groups
receiving 50 mg/kg linezolid alone or in combination with
rifampin (groups 4 and 7) when compared to the untreatedTable 1 Outcome of 7-day treatment of experimental mediastinit
Group Drug and dose
Group 1 (Uncontaminated
control)
No drug
Group 2 (Untreated
contaminated control)
No drug
Group 3 Linezolidc (25)
Group 4 Linezolidc (50)
Group 5 Rifampind (5)
Group 6 Linezolidc (25) + rifampind (5)
Group 7 Linezolidc (50) + rifampind (5)
a Log10CFU/ml  SD.
b Log10CFU/g  SD.
c Administered intraperitoneally twice daily.
d Administered intramuscularly twice daily.
e p < 0.05 vs. the mean bacterial counts of the mediastinum in grou
f p < 0.05 vs. the mean bacterial counts of the sternum in groups 2,contaminated group (group 2) and groups receiving 25 mg/kg
linezolid, rifampin, or their combination (groups 3, 5, and 6;
p < 0.05). However, there was no statistically significant
difference in terms of mean bacterial counts between the
25 mg/kg linezolid monotherapy group and the 25 mg/kg
linezolid plus rifampin group (group 6; p > 0.05). The same
difference was also found between the 50 mg/kg linezolid
monotherapy and rifampin combination groups. Finally,
there was no mortality among the rats and we did not
encounter any clinical evidence of drug-related adverse
effects, such as local signs of perigraft inflammation, anor-
exia, vomiting, diarrhea, or alteration in behavior.
Discussion
In this study of experimental mediastinitis caused by MRSA,
treatment with linezolid at 50 mg/kg was found to be effec-
tive in reducing the bacterial count in mediastinum and
sternum, whereas the same efficacy was not observed at
25 mg/kg. The combination of linezolid and rifampin was not
able to significantly change the treatment results when
compared with those obtained with linezolid alone.
There are reports of several clinical and experimental
studies of linezolid alone or in combination with rifam-
pin;16,17,24 however, its exact efficacy and safety in post-
sternotomy mediastinitis have not been well reported. Jac-
queline et al.25 found that linezolid plus rifampin was the
most active combination against MRSA strains in comparison
with gentamicin and vancomycin in time—kill experiments. In
vivo studies of the linezolid—rifampin combination in an
MRSA bacteremia model and a methicillin-sensitive S. aureus
(MSSA) endocarditis model have shown additivity or indiffer-
ence.18,19 The purpose of our study was to evaluate the
efficacy of linezolid as a treatment agent for MRSA medias-
tinitis and to investigate whether linezolid can provide
synergistic activity when given in combination with rifampin
in the treatment of that serious infection. Based on prior
experimental and clinical research on MRSA infections,18,26—
29 we developed an experimental mediastinitis model.is caused by methicillin-resistant Staphylococcus aureus (MRSA)
No. culture
negative/total
Mean bacterial count
Swab Sternum Mediastinuma Sternumb
10/10 10/10 0.0 0.0
0/10 0/10 5.20  0.15 5.59  0.20
0/10 0/10 4.68  0.28 5.18  0.20
2/10 2/10 2.49  1.32e 2.59  1.38 f
0/10 0/10 4.87  0.07 5.25  0.20
0/10 0/10 4.85  0.10 5.21  0.19
1/10 1/10 2.97  1.05e 3.06  1.08 f
ps 2, 3, 5, and 6.
3, 5, and 6.
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agents has been widely investigated in cardiovascular infec-
tions. The increasing prevalence of MRSA in cardiac surgery
units has led to increased vancomycin utilization for these
serious and life-threatening infections seen in these units.30—
34 Since the emergence of glycopeptide intermediate and
resistant S. aureus,35,36 clinicians have understood the
importance of minimizing glycopeptide use.
In order to choose a proper treatment and prevent unne-
cessary use of broad-spectrum antibiotics, an exact defini-
tion of post-sternotomy mediastinitis should rely on both
clinical and bacteriological criteria. This is especially impor-
tant with regard to infections caused by MRSA, as these
infections have a comparatively worse clinical outcome.5,37
Linezolid has been demonstrated to be effective in the
clinical management of MRSA infections.23,38,39 We investi-
gated the activity of linezolid in an experimental model of
mediastinitis due to MRSA, because analogous infections in
humans are common in clinical practice and generally require
aggressive surgical debridement and prolonged courses of
systemic antimicrobial treatment.
The dose of linezolid was selected to mimic the thera-
peutic dose given to patients, and was also based on dose
regimens used in other animal models of infection. A 25-mg/
kg oral dose of linezolid in rats produces plasma exposures
comparable to those obtained in humans following a 600-mg
oral dose.40—42 The approximately 100% bioavailability of
linezolid allows the drug to be administered either parent-
erally or orally in the same dose without requiring a dose
adjustment.43 The excellent bioavailability of linezolid in
rats has also been demonstrated.28
We used a normal dose and a higher dose, as our MRSA
strain was less susceptible in vitro. For the same reason Jabes
et al.42 used linezolid at 50-, 100-, and 200-mg/kg doses once
orally in rats infected with MRSA. Based on the pharmacoki-
netics of linezolid against the strain tested, they expected
the dose of 50 mg/kg to be effective against MRSA. But this
dose was found to be ineffective in reducing the bacterial
load of the MRSA strain. A 100-mg/kg oral dose of linezolid
was found to be necessary to achieve an adequate reduction
in bacterial titer.
Oramas-Shirey et al.44 reported that a 25-mg/kg intrave-
nous dose of linezolid given three times a day for 5 days was
not effective in the treatment of experimental staphylococ-
cal endocarditis in a rabbit model, whereas doses of 50 or
75 mg/kg with the same treatment schedule were found to
be effective.
The efficacy of linezolid at 50 mg/kg/day or 100 mg/kg/
day in a rat model of pneumococcal pneumonia has also been
evaluated, and the latter was found to be more effective.25
As linezolid has not been extensively investigated in cardi-
ovascular infections, and there have been reports of treat-
ment failure in another serious cardiovascular infection
endocarditis with the standard dose used in humans,45 we
decided to investigate the efficacy of linezolid at a double
dose in mediastinitis and compare it with the standard dose.
We found that linezolid at a double dose was effective in
reducing the bacterial count in mediastinum and sternum.
We did not observe any side effects with the high dose, but
this requires confirmation in future studies in humans.
Additionally, our results demonstrated that adding rifam-
pin to linezolid treatment did not change the results obtainedwith linezolid alone. This is especially important in practice,
as clinicians should alsominimize rifampin utilization in order
to avoid rifampin resistance.
Linezolid at 50 mg/kg seemed to be an effective agent in
our experimental mediastinitis model, and this result sug-
gests that this antibiotic may be a reasonable therapeutic
choice. Unfortunately, although the possibility of acquired
resistance to linezolid is low, there are recent studies report-
ing a risk of linezolid resistance after exposure to this
drug.46—48 This is why it should be considered only for
patients with serious MRSA infections that are poorly respon-
sive to the glycopeptides or those who do not tolerate
glycopeptide treatment.
More clinical studies are required on the combination of
linezolid with other antimicrobial agents in order to increase
the bactericidal activity of therapy, to prevent the emer-
gence of drug-resistant subpopulations, and to provide a
complementary antibacterial spectrum.
When considering our results, the following limitations of
our study need to be taken into account. Our in vivo model
used a direct form of MRSA inoculation in the mediastinal and
in the sternal layers. Additionally, we did not determine
serum antibiotic concentration in the rats. Unfortunately,
the required technical equipment for measuring the anti-
biotic concentration is not present in our hospital as we live in
a country with limited financial resources. We used linezolid
in a dose that mimics the validated human dose and its double
form, and investigated its efficacy by evaluating the presence
and the amount of the staphylococcal strains in the infected
area. However, the animal model in this study is not directly
comparable with the real situation in a living human being.
In conclusion, linezolid at 25 mg/kg, rifampin, and the
combination of linezolid at 25 mg/kg and rifampin did not
significantly reduce the bacterial counts and were found to
be ineffective in the treatment of our experimental medias-
tinitis model. The combination of rifampin with linezolid
therapy did not result in a significant change in bacterial
counts versus linezolid alone. Finally, increasing the dose of
linezolid from 25 mg/kg to 50 mg/kg resulted in a significant
reduction in bacterial counts. Based on our findings, high-
dose linezolid should be considered as a possible therapeutic
agent for the treatment of post-sternotomy infection caused
by MRSA. Our results need to be confirmed in further pre-
clinical and clinical studies.
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